Efficacy of Accelerated Streptokinase Infusion in the Treatment of St-Elevation Myocardial Infarction
DOI:
https://doi.org/10.37762/jgmds.10-1.338Keywords:
Accelerated Streptokinase, Acute ST-Elevation Myocardial Infarction, EfficacyAbstract
OBJECTIVES
To determine the efficacy of accelerated streptokinase (SK) in patients with acute ST-elevation myocardial infarction (STEMI).
METHODOLOGY
This Descriptive study was done in the Department of Cardiology, Hayatabad Medical Complex over a period of 6 months from august 2020 to February 2021. Age ranged between 35-70 years. Both males and females presenting with acute ST elevation MI, patients within 6 hours of the onset of chest pain were included in the study.
RESULTS
Among 144 patients age distribution was analyzed as 50(35%) patients were in age 35-50 years, and 94(65%) patients were in age 51-70 years. The mean age and standard deviation were 61± 8.19. Gender distribution was analyzed as 88(61%) patients were male and 56(39%) patients were female. Status of BMI was analyzed as 69(48%) patients had BMI ≤27 Kg/m2 and 75(52%) patients had BMI >27 Kg/m2.
CONCLUSION
The accelerated SK infusion regimen of 1.5 MU in 20 min is safe and well tolerated with significantly faster and higher clinical reperfusion rates, more preserved LV systolic function, less atrial and ventricular sustained arrhythmias, and less in-hospital and 1-year mortality rates in acute STEMI.
Downloads
Metrics
References
Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020 Oct 13. 4(19):4693-738
Proctor P, Leesar MA, Chatterjee A. Thrombolytic therapy in the current ERA: myocardial infarction and beyond. Current Pharmaceutical Design. 2018 Feb 1;24(4):414-26
Hawkes MA, Carpani F, Farez MF, Ameriso SF. Door-to-needle time in acute stroke treatment and the “July Effect”. The Neurohospitalist. 2018 Jan;8(1):24-8
Liu C, Xie J, Sun S, Li H, Li T, Jiang C, Chen X, Wang J, Le A, Wang J, Li Z. Hemorrhagic transformation after tissue plasminogen activator treatment in acute ischemic stroke. Cellular and Molecular Neurobiology. 2020 Oct 30:1-26
Prince MJ, Wu F, Guo Y, Robledo LM, O'Donnell M, Sullivan R, Yusuf S. The burden of disease in older people and implications for health policy and practice. The Lancet. 2015 Feb 7;385(9967):549-62
Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, Wei L, Mony P, Mohan V, Gupta R, Kumar R. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. The Lancet. 2016 Jan 2;387(10013):61-9
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, De Ferranti S, Després JP, Fullerton HJ, Howard VJ. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. circulation. 2016 Jan 26;133(4):e38-60
Joseph P, Yusuf S, Lee SF, Ibrahim Q, Teo K, Rangarajan S, Gupta R, Rosengren A, Lear SA, Avezum A, Lopez-Jaramillo P. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. Heart. 2018 Apr 1;104(7):581-7
Thiele H, Akin I, Sandri M. Non-Culprit Lesion PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. JCOM. 2018 Mar;25(3)
Vergara R, Valenti R, Migliorini A, Cerisano G, Carrabba N, Giurlani L, Antoniucci D. A new risk score to predict long-term cardiac mortality in patients with acute myocardial infarction complicated by cardiogenic shock and treated with primary percutaneous intervention. The American journal of cardiology. 2017 Feb 1;119(3):351-4
Prabhakaran K, Mukandan PK. THROMBOLYTIC THERAPY IN STEMI--RELEVANCE IN CURRENT WORLD OF INTERVENTIONAL CARDIOLOGY. Journal of Evolution of Medical and Dental Sciences. 2018 Jan 8;7(2):181-3
Alam MA, Hayat Y, Jadoon SA, Munazza B, Nazir A, Ali W. Efficacy of streptokinase in diabetic patients with acute st elevation myocardial infarction. Pakistan Journal of Physiology. 2019 Mar 31;15(1):10-2
Ramya NS, Narendra JB, Raghavulu V, Babu MS, Teja ND, Malini KH, Prathap SS. Assess the clinical efficacy of streptokinase in thrombolysed patients of acute ST segment elevation myocardial infarction. Journal of Young Pharmacists. 2018;10(3):330
Ahmad M, Yasir M, Rahmat A. ACUTE ST ELEVATION MYOCARDIAL INFARCTION: 70% OR MORE ST SEGMENT RESOLUTION ON 90 MINUTES POST THROMBOLYSIS ELECTROCARDIOGRAM AS A PREDICTOR OF IN HOSPITAL OUTCOMES. The Professional Medical Journal. 2018 May 10;25(05):777-83
Siriwattana K, Kuanprasert S, Wijarnpreecha W, Detnuntarat P, Chotayaporn T, Lertthanaphol K, Onieum N. Accelerated Streptokinase versus Standard Dose Streptokinase in ST-Elevation Myocardial Infarction in Nakornping Hospital. Journal of the Medical Association of Thailand. 2020 Feb 1;103(2):172-8
Bendary A, Tawfik W, Mahrous M, Salem M. Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen. Journal of Cardiovascular and Thoracic Research. 2017;9(4):209
Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. The Lancet. 2017 Jan 14;389(10065):197-210
Ghaffari S, Kazemi B, Golzari IG. Efficacy of a new accelerated streptokinase regime in acute myocardial infarction: a double blind randomized clinical trial. Cardiovascular therapeutics. 2013 Feb;31(1):53-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Umer Shafiq, Muhammad Abdul Wahab, Syed Kashif-Ur-Rahman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
